Clinical Trials Directory

A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for The Treatment of Recurrent or Persistent Endometrial Carcinoma

This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer. The safety, tolerability, and pharmacokinetics of GDC-0980 will also be evaluated.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : GDC-0980

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Patients must have recurrent or persistent endometrial carcinoma that is refractory to curative therapy or established treatments - Histologic confirmation of the original primary tumor is required - Histologic or cytologic confirmation of the recurrent/progressive disease is desired - Patients must have had at least one but no more than two prior chemotherapeutic regimens for management of endometrial carcinoma - Disease that is measurable per RECIST v1.1 - No active infection requiring antibiotics - Any hormonal therapy directed at the malignant tumor must be discontinued at least 2 weeks prior to first study treatment - Any other prior therapy directed at the malignant tumor, including immunologic agents and radiotherapy, must be discontinued at least 2 weeks prior to first study treatment - Adequate hematologic and end organ function

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting

Footer Links: